China Temozolomide Industry 2015-2019 Research Report adds “Investigation Report on China Temozolomide Market, 2010-2019”to its store.


Among all anti-tumor drugs, alkylating agent boasts of the longest history of application. Since nitrogen mustard was used to treat malignant lymphoma in 1942, alkylating agent has become the first-line anti-tumor drug due to its cheap price. The major varieties of alkylating agent are temozolomide and oxaliplatin. First developed by Schering-Plough, temozolomide was approved by FDA to treat glioma in 1999 and entered China since 2000.

Having efficacy in glioma, leukemia, melanoma, lymphoma and solid tumor, temozolomide can easily penetrate through blood-brain barrier and stay stable in acid environment with a broad antitumor spectrum and low toxicity. And it can be taken orally in patients who have drug resistance to nitrosoureas.

According to relevant statistics, about 60% of primary brain tumors are malignant ones. The incidence of malignant brain tumor in China is 80-100/1 million and the annual number of new cases is over 200,000. Temozolomide has reported a remarkable growth in global sales since its debut.

Purchase a copy of this report @ .

According to CRI's market survey, the sales value of temozolomide in sample hospitals rose from about CNY 6 million in 2006 to over CNY 300 million in 2014 with CAGR during the period of 2008-2014 reaching up to 67%. In 2014, the generic drug of temozolomide made by Tasly was approved to enter the market. Currently, temozolomide products available in the Chinese market come from the following four companies: Jiangsu Tasly Diyi Pharmaceutical Co., Ltd, Orion (Finland), Schering-Plough and Beijing SL Pharmaceutical Co., Ltd, among which the former three dominate the market and Orion (Finland) had the largest market share of about 50.5% for sales value in 2014.

Readers can get at least the following information through this report:

-market size of temozolomide in China

-competitive landscape of temozolomide market in China

-price of temozolomide made by different enterprises in China

-market outlook of temozolomide in China

The author suggests the following groups of people purchase this report:

- manufacturers of anti-tumor agents

-investors/research institutions interested in Chinese medicine market

--any interest in Chinese medicine market, please contact CRI for customized survey service

Companies Mentioned

Jiangsu Tasly Diyi Pharmaceutical Co., Ltd; Orion; Schering-Plough; Beijing SL Pharmaceutical Co., Ltd

Table of Contents

1 Related Concepts of Temozolomide

1.1 Indication

1.2 Sales Status in Global Market

2 Market Profile of Temozolomide in China

2.1 Patent and Approval Information of Temozolomide in China

2.2 Major Manufacturers

2.3 Market Size

3 Survey on Temozolomide Sales in China, 2010-2014

3.1 Sales Value

3.1.1 Overall Sales Value

3.1.2 Sales Value by Regions

3.2 Sales Volume

3.2.1 Overall Sales Volume

3.2.2 Sales Volume by Regions

4 Survey on Market Share of Major Temozolomide Manufacturers in China, 2010-2014

4.1 Market Share by Sales Value

4.2 Market Share by Sales Volume